Short answer
Teladoc Health, Inc. (TDOC) filed an 8-K current report with the SEC on August 31, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Michael Grasher appointed CFO effective August 31, 2026, ending interim CFO arrangement while Charles Divita remains CEO.
Teladoc Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Michael Grasher appointed CFO effective August 31, 2026, ending interim CFO arrangement while Charles Divita remains CEO
- $550,000 annual salary, $500,000 sign-on bonus, and 85% target annual bonus beginning 2027
- Approximately $3.0 million new-hire equity award, split 50% RSUs and 50% performance stock units
- Performance awards tied to 2026 adjusted EBITDA and 2026–2028 revenue CAGR, aligning compensation with operating targets
- Severance includes 12 months’ salary normally, extending to 18 months plus full unvested service-based equity vesting after qualifying change-of-control termination
Item 7.01 · Regulation FD Disclosure
- Appointment of Mr. Grasher as Teladoc’s Chief Financial Officer
- CFO transition potentially affecting financial oversight, capital allocation, and investor communication
- Press release furnished as Exhibit 99.1 for appointment details and effective timing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Teladoc Health, Inc. 8-K filings
Get the next TDOC 8-K as it lands
Follow TDOC for push alerts, or ask the research agent what this filing means.